GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Shares Outstanding (EOP)

ADTX (Aditxt) Shares Outstanding (EOP) : 0.53 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aditxt Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aditxt's shares outstanding for the quarter that ended in Sep. 2024 was 0.53 Mil.

Aditxt's quarterly shares outstanding increased from Jun. 2024 (0.05 Mil) to Sep. 2024 (0.53 Mil). It means Aditxt issued new shares from Jun. 2024 to Sep. 2024 .

Aditxt's annual shares outstanding increased from Dec. 2022 (0.00 Mil) to Dec. 2023 (0.03 Mil). It means Aditxt issued new shares from Dec. 2022 to Dec. 2023 .


Aditxt Shares Outstanding (EOP) Historical Data

The historical data trend for Aditxt's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Shares Outstanding (EOP) Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial - - - - 0.03

Aditxt Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.04 0.05 0.53

Competitive Comparison of Aditxt's Shares Outstanding (EOP)

For the Biotechnology subindustry, Aditxt's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aditxt's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Aditxt's Shares Outstanding (EOP) falls into.



Aditxt Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Aditxt  (NAS:ADTX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Aditxt Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Aditxt's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aditxt Business Description

Industry
Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Executives
Charles Athle Nelson director 11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp 10 percent owner 787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes officer: Chief Legal Officer and GC 737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley officer: PRINCIPAL ACCOUNTING OFFICER 2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge director C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna officer: CHIEF OPERATING OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne officer: CHIEF FINANCIAL OFFICER BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony director LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna director, officer: CHIEF EXECUTIVE OFFICER 871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang director, officer: CHIEF INNOVATION OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354